Articles On Medibio (ASX:MEB)

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a rocky two weeks for small-cap health companies with 42 gaining ground, 76 losing it, and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. CODE COMPANY PRICE 1 WEEK RETURN %...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX started the week lower as a result of a drop in the energy and financial sectors. Energy shares fell by over 3%, as surging cases of the Omicron variant raised fears that new restrictions may hit fuel demand. Financials meanwhile we...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

J-Pow and the gang are back on deck with a bang later tonight, and ASX investors appeared to buckle up in the safety seat ahead of the all-important Fed meeting. The ASX 200 finished around 0.7% lower, with a steeper fall of 1.4% in the mic...

It’s been a rocky two weeks for small-cap health companies, with 27 companies gaining ground, 89 losing it and 21 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Name Price % Six Mont...

It’s been a rocky two weeks for small-cap health companies, with 33 companies gaining ground, 86 losing it and 16 flatlining.   Here’s a table showing how ASX-listed healthcare stocks have been performing. Code Company Price % Six M...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX started the week on a downward note with tech leading the laggards despite one of Australia’s major unicorns joining the bourse and gaining over 30%. SiteMinder (ASX:SDR), a hotel commerce platform, listed on the ASX at $5.06 per sh...

Local stocks posted a solid session on Wednesday ahead of this week’s main event on global markets later tonight — the US Fed’s latest policy decision. After plenty of forward guidance, the Fed is expected to formally announce the taper of...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

The ASX finished in the green by just 0.03%. Today’s gain was spurred by a 1.34% rally in tech shares as well as a rally in Crown (ASX:CWN) shares in the wash-up of the Victorian government’s royal commission. Despite the report finding the...

Just like yesterday the ASX rallied for most of the day but retreated in the afternoon and today closed in the red. The ASX 200 was down 0.08% at 7,375 points. Another difference from yesterday was tech was the best sector gaining 1.7% whil...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Highlights  Many sectors have incurred sharp losses as the pandemic began. However, most stocks rebound over time. Some mineral exploration and healthcare firms have gained over 50% in the last month. BNL, MEB, MCE and WCB shares flar...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

On a day Facebook was out for 6 hours, the tech sector – in Australia and abroad – was sold off and that was enough to send the ASX into negative territory. The ASX 200 closed 0.41% down at 7,248 points and tech was easily the worst sector,...

Each week, Stockhead recaps ASX stocks that are “running hot” as deduced by the Relative Strength Index (RSI). The RSI is a technical gauge which measures how trading momentum is affecting the price action. A reading of 70 is seen as the le...

Although earnings results were the main theme in August, there were also some notable healthcare breakthroughs on the ASX. Dimerix (ASX:DXB) jumped 45% during the month after announcing the commencement of ACTION 3, a Phase III study in pat...

It’s been a mixed two weeks for small-cap health companies, with only 45 companies gaining ground, 76 losing it and 23 flatlining. Rhinomed (ASX:RNO) was the biggest gainer, up a massive 85% for the fortnight after scoring a contract with N...

The ASX 200 finished lower for the second consecutive day, falling lower by 0.94% today as COVID-19 cases continue to rise in Australia and across the globe. Health Minister Greg Hunt however said that more than 10 million Australians have...

The ASX 200 health stocks index is tracking the broader index well over the past two weeks. Both the XHJ Health Sector and the ASX 200 benchmark rose by 3% over this period. A handful of ASX health stocks have seen their prices skyrocket du...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a mixed two weeks for small-cap health companies, with only 38 companies gaining ground, 74 losing it and 21 flatlining. Analytica Limited (ASX:ALT) was the biggest gainer, up 25% from 8 to 20 July, followed by  Rhinomed (ASX:RNO)...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

It’s been a mixed two weeks for small-cap health companies, with 60 companies gaining ground and 52 losing it – and 21 flatlining. Botanix Pharma Ltd (ASX:BOT) was the biggest gainer, up 38% from 23 June to 7 July, and Suda Pharmaceuticals...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade.   WINNERS Scr...

Wall Street climbs on Biden stimulus All three major US benchmarks rose on Thursday, as President Biden announced a US$579 billion stimulus. The Dow Jones rose by 0.95%, S&P 500 by 0.58%, and tech-heavy Nasdaq hit another record, rising...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Here’s our fortnightly wrap of all the news driving ASX health stocks. The healthcare sector has returned 2.3 per cent for the last two weeks, compared to the broader market which rose by 2.7 per cent. The biggest news globally was out of U...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers during the trading day. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intrad...

Stockhead’s Top 10 at 10, published at 10.15am each trading day, highlights the best (and worst) performing ASX small caps in morning trade using live data. It’s a short, sharp update to help frame the trading day by showing the biggest mov...

Summary Drug development and clinical services company Emyria has obtained Class IIa TGA registration for its medical-grade monitoring tool, Openly. With this TGA registration, Emyria is in a leading position to develop Real World Evid...

Australia’s digital and technology sector got a major boost in last night’s Federal Budget, with the government announcing a total of $1.2 billion spending for the whole sector. Part of that, or around 10 per cent, will be used to support t...

Summary GBR share price has skyrocketed by a massive 91.3% to AU$0.088. Eve Investments’ confirmed first purchase order has led its share price to rise by 16.67% to AU$0.007. BOE’s share price opened with a gap and surpassed its 52-we...

Summary Digital health player ResApp Health has entered into a non-exclusive distribution agreement with Ilara Health. Recce Pharmaceuticals stated that RECCE® 327 had shown bactericidal activity against ESKAPE pathogens, including the...

Summary Medicinal cannabis player Botanix Pharmaceuticals Limited has provided a clinical development update of the BTX 1801 antimicrobial platform. Botanix’s BTX 1801 was safe, well-tolerated, clinically effective in the Phase 2a stud...

Medibio (ASX:MEB) says it has been awarded a patent from the US Patent and Trademark Office for its 'Method and System for Assessing Mental State'.

Australians will continue to work from home (WFH) way beyond the pandemic – at least that’s according to the latest data out of the Australian Bureau of Statistics (ABS). In the latest survey, the ABS reported that 30 per cent of Australian...

Summary Pharmaxis Ltd and Charlie Teo Foundation have identified a new drug that shows promise in tackling a deadly form of brain cancer. Pharmaxis’ PXS-5505 will be a part of preclinical testing to assess its efficacy for glioblastoma...

The capital raisings boom on the ASX is continuing in 2021 with nearly $10 billion raised in the first four months of the year. Across 325 deals, ASX companies have raised $9.878 billion in capital amidst IPOs, placements and rights issues....

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Summary Neuren Pharmaceuticals obtained a Canadian patent grant for trofinetide, with a patent term that extends to January 2032. Health technology company Medibio Limited has secured a pre-submission meeting with the FDA for a new 510...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest winners and losers. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday trade. WINNERS Scrol...

Summary Amplia Therapeutics has obtained data from an animal study demonstrating its FAK inhibitors lower fibrosis arising from the NASH. The positive data from the animal study is anticipated to support the future development and part...

Closing Bell is Stockhead’s daily recap of the ASX’s biggest movers – the winners and losers alike. Data is taken at the market close – at 4.10pm AEDT. Stocks highlighted in yellow rose (or fell) after making announcements during intraday t...

If there’s one thing that the pandemic has changed irreversibly in our lives, it’s got to be the way we work. A recent McKinsey study shows that 20 per cent of the global workforce will work from home between three to five days a week post-...